Insight Pharmaceuticals to launch $310 million facilities on Thursday

By Paul A. Harris

Portland, Ore., Oct. 2 - Insight Pharmaceuticals, LLC plans to launch $310 million of credit facilities (expected ratings B1/B+) via GE Capital on Thursday, according to a market source.

The deal is comprised of a $20 million four-year revolver and a $290 million four-year first-lien term loan.

Pricing is Libor plus 500 basis points with a 1.25% Libor floor at 99.5. The facilities have 101 soft call protection for one year.

Proceeds will be used to refinance the company's existing first-lien term loan, along with a $38 million upsizing.

A $112 million amount of the existing second-lien debt stays in place.

Insight Pharmaceuticals is a Langhorne, Pa.-based marketer and distributor of branded over-the-counter pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.